Pet food transparency push returns to FDA: full analysis

A consumer advocacy fight over pet food labeling is back in front of the FDA. Susan Thixton, writing for Truth about Pet Food, said the Association for Truth in Pet Food filed a petition for reconsideration after FDA denied the group’s earlier request to require disclosure of feed grade ingredients on pet food labels. The reconsideration filing, dated April 2026, argues that current labels can leave pet parents unable to tell whether ingredients come from materials that meet human food standards or from feed-grade sources. (truthaboutpetfood.com)

The new filing follows a much older campaign. Thixton’s 2022 citizen petition asked FDA to require subclass disclosure for feed grade ingredients and argued that using the same ingredient names for feed-grade and human food-grade materials is misleading. In the new post, Thixton said FDA took 1,333 days to respond, then refused the request. FDA’s petition process allows parties to seek reconsideration of an agency decision, though the agency notes that reviews can take weeks to more than a year depending on complexity. (truthaboutpetfood.com)

At the center of the dispute is the meaning of “feed grade,” a term that is widely used in industry and advocacy discussions but not presented to shoppers as a required front-of-pack disclosure. The reconsideration petition argues that FDA has not justified its statement that it has “no reason to think” there is a difference between certain feed-grade and USDA-inspected ingredients, and it points specifically to poultry ingredients that do not conform to federal meat or poultry inspection laws. The petition also argues that labels using phrases such as “made with real chicken” and images of cooked meat may imply a quality level that is not actually disclosed elsewhere on the package. (truthaboutpetfood.com)

FDA’s current public guidance presents a more conventional regulatory picture. The agency says pet food ingredients generally must be listed by their common or usual names, and that AAFCO-defined ingredient names may serve as common usage names. FDA also says it works with state agencies and AAFCO, while AAFCO itself emphasizes that it does not regulate or approve individual labels; states do that under their own feed laws. In other words, the system Thixton is challenging is not just federal, but a long-standing federal-state model built around AAFCO definitions and state enforcement. (fda.gov)

There are also signs that labeling oversight is already in flux. AAFCO adopted Pet Food Label Modernization and, in a 2025 resolution, acknowledged ongoing inconsistency in label review across states even as regulators work toward more uniform interpretation. That does not directly address Thixton’s demand for feed-grade disclosure, but it does show that pet food labeling remains an active policy area, with regulators trying to make labels easier to understand while preserving state authority. (aafco.org)

Direct expert reaction to this specific reconsideration filing appears limited so far. In the materials available, the most developed arguments come from Thixton’s own petition and FDA’s general guidance rather than outside veterinary nutrition or regulatory experts commenting publicly on the April 2026 filing. Based on those sources, the core disagreement is less about whether pet food can legally use animal-feed ingredients and more about whether current naming and marketing practices give pet parents enough information to distinguish ingredient grade and sourcing. That is an inference from the filings and agency guidance, rather than a stated FDA conclusion. (truthaboutpetfood.com)

Why it matters: For veterinary teams, this is a labeling story with practical exam-room implications. Pet parents increasingly ask clinicians to interpret ingredient panels, explain “human grade” versus standard commercial diets, and help them reconcile marketing claims with evidence-based nutrition. If the debate over feed-grade disclosure grows, clinics may see more questions about what ingredient terms actually mean, how much label language reflects regulatory categories versus marketing, and whether quality claims correlate with nutritional adequacy or safety. FDA’s own guidance continues to anchor oversight in ingredient naming, claims review, and coordination with states, so any shift here could ripple into how products are marketed and discussed in practice. (fda.gov)

What to watch: The next signal will be procedural: whether FDA acknowledges the reconsideration petition in the docket and whether it issues a substantive response. Longer term, watch for this issue to surface in broader pet food labeling debates, especially as AAFCO and state regulators continue modernization work and industry faces ongoing pressure for clearer, more standardized consumer-facing disclosures. (fda.gov)